Pantelis Sarafidis, Rajiv Agarwal, Bertram Pitt, Christoph Wanner, Gerasimos Filippatos, John Boletis, Katherine R Tuttle, Luis M Ruilope, Peter Rossing, Robert Toto, Stefan D Anker, Zhi-Hong Liu, Amer Joseph, Christiane Ahlers, Meike Brinker, Robert Lawatscheck, George Bakris
Background Patients with stage 4 chronic kidney disease (CKD) and type 2 diabetes have limited treatment options to reduce their persistent cardiovascular and kidney risk. In FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, finerenone improved heart-kidney outcomes in participants with CKD and type 2 diabetes. Methods This FIDELITY subgroup analysis investigated the effects of finerenone in participants with stage 4 CKD (estimated glomerular filtration rate [eGFR] <30 ml/min/1.73 m2)...
March 17, 2023: Clinical Journal of the American Society of Nephrology: CJASN